Advanced Regen Medical Technologies, LLC

Steven John Greco

Vincent C Giampapa

Pranela Rameshwar

Seda Ayer

Khadidiatou Guiro

A method comprising (a) obtaining young adult stem cells (YASC) from a first subject; (b) lysing the YASC to generate a lysate comprising an intracellular matrix (ICM) and other cellular components; (c) filtering the lysate through a filter having a membrane size of equal to or less than 0.4 micron to obtain a filtrate; and (d) applying the filtrate to a culture of aged adult stem cells (AASC) for a time period ranging from about 24 hours to about 30 days to generate a reprogrammed AASC (R-AASC) wherein the AASC were obtained from a second subject and wherein the R-AASC when infused into a breast cancer stem model results in a reduced number of breast cancer cells in bone marrow in comparison to a breast cancer stem model having AASC that have not been reprogrammed.

Reprogramming of aged adult stem cells

A method comprising administering to a subject a composition comprising an isolated microRNA having a sequence selected from the group consisting of miR-19a-3p (SEQ ID NO:1); miR-103a-3p (SEQ ID NO:2); miR-106b-5p (SEQ ID NO:3); miR-146a-5p (SEQ ID NO:4); miR-223-5p (SEQ ID NO:5); miR-4497 (SEQ ID NO:6); miR-1303 (SEQ ID NO:7); miR-619-5p (SEQ ID NO:8); miR-1273f (SEQ ID NO:9); miR-7851-3p (SEQ ID NO:10); a functional variant thereof; and combinations thereof.

Microrna compositions and methods of making and using same

A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.

Cell free compositions for cellular restoration and methods of making and using same

Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg/Mndependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.

Growing community of inventors

Houston, TX, United States of America

Steven John Greco